
Ep192: Kate Haviland on Following the Science to Precision Immunology
8.1.2026
0:00
1:26:06
Kate Haviland, former CEO of Blueprint Medicines, on how the company transitioned to a precision immunology company and was acquired by Sanofi for $9.5 billion.
Weitere Episoden von „The Long Run with Luke Timmerman“



Verpasse keine Episode von “The Long Run with Luke Timmerman” und abonniere ihn in der kostenlosen GetPodcast App.







